Instala Flash per poder visualitzar el vídeo
A recently published study has identified a mutation that relieves the seriousness of neurological symptoms with aura associated with migraine, one of the most common headaches that lead to the highest degree of incapacity, and affects up to 8% of men and up to 20% of women in industrialised countries.
The Neuropharmacology Laboratory (Neurophar) of the Department of Experimental and Health Sciences (CEXS) of UPF, directed by professor Rafael Maldonado, is participating in the NEOGENIUS PHARMA project financed by the CDTI (Center for Technological and Industrial Development) in the 2009 call of the CENIT programme
The project is led by the Catalan pharmaceutical companies Almirall, S.A; Laboratorios Dr. Esteve, S.A; Palau Pharma, S.A and the Basque biotechnology company Proteomika, S.L., which form the consortium NEOGENIUS PHARMA, AIE. The total budget is 21,548,378 euros and Neurophar’s of which share is 560,000 euros.
[+]SoIBio is a new International Scientific Society which purpose is to work in the field of computational biology and bioinformatics in South America. It was founded last October, 26th in Puerto Morelos (Mexico) with the participation of scientifics and researchers of most of South American countries, Spain and Portugal. Nuria B. Centeno, researcher of GRIB (IMIM/UPF) has participated in that meeting representing our Group and will take part of the Exchange and Collaboration Comission.
[+]